VIU Set to Launch First Psychedelics Therapy Cours
Post# of 160
(Total Views: 466)
Posted On: 02/24/2022 4:32:10 PM
VIU Set to Launch First Psychedelics Therapy Course in Canada
Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services.
Shannon Dames, the institution’s nursing professor, stated that this launch was significant because it recognized that psychedelic-assisted therapy was an advanced practice that required a unique skill set.
Laura McLean, one of the program’s registrants, signed up after she tried therapy under Roots to Thrive. Roots to Thrive is a 12-week program with virtual sessions that feature guided discussions and the use of ketamine for three sessions for those interested. McLean revealed that the program helped her let go of some fears she didn’t even know she had, adding that she finished the program with more confidence. She noted that this program was the start of a movement.
The curriculum will be delivered in collaboration with cultural safety experts, Indigenous professionals and Geraldine Manson, the institution’s elder-in-residence. The therapy will take a different approach to mental health. Dames explained that the therapy was essentially a way for individuals to access stuck emotions or stuck energies, sit with and process those emotions and energies, and then speak with experts about the experience.
Healthcare professionals involved in the field believe that psychedelic-assisted therapy could be particularly helpful for individuals who struggling with treatment-resistant mental health conditions, post-traumatic stress disorder and end-of-life distress.
Dr. Susan Abbey, a psychiatrist, noted that despite the need for more research, there was a lot of promise and excitement around the field of psychedelic therapy. Abbey is with the University Health Network in Toronto, which plans to use a $5 million donation it received from the Nikean Foundation to build a research center in the country. The first project to be conducted by the university’s research center will examine combining psychedelics and end-of-life distress. Abbey notes that a number of studies have demonstrated that the substances may help individuals suffering from end-of-life distress.
The research center also plans to study whether therapists need to use the drug compounds themselves and experience them in order to be better equipped to facilitate the treatment. Vancouver Island University’s part-time program is set to start this fall, with registration open until March 31, 2022.
Now that major academic institutions such as VIU are beginning to offer courses in psychedelic-assisted therapy, it may just be a matter of time before the psychedelic formulations of sector players such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) experience a surge in demand once the public becomes aware of their approval by regulators.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services.
Shannon Dames, the institution’s nursing professor, stated that this launch was significant because it recognized that psychedelic-assisted therapy was an advanced practice that required a unique skill set.
Laura McLean, one of the program’s registrants, signed up after she tried therapy under Roots to Thrive. Roots to Thrive is a 12-week program with virtual sessions that feature guided discussions and the use of ketamine for three sessions for those interested. McLean revealed that the program helped her let go of some fears she didn’t even know she had, adding that she finished the program with more confidence. She noted that this program was the start of a movement.
The curriculum will be delivered in collaboration with cultural safety experts, Indigenous professionals and Geraldine Manson, the institution’s elder-in-residence. The therapy will take a different approach to mental health. Dames explained that the therapy was essentially a way for individuals to access stuck emotions or stuck energies, sit with and process those emotions and energies, and then speak with experts about the experience.
Healthcare professionals involved in the field believe that psychedelic-assisted therapy could be particularly helpful for individuals who struggling with treatment-resistant mental health conditions, post-traumatic stress disorder and end-of-life distress.
Dr. Susan Abbey, a psychiatrist, noted that despite the need for more research, there was a lot of promise and excitement around the field of psychedelic therapy. Abbey is with the University Health Network in Toronto, which plans to use a $5 million donation it received from the Nikean Foundation to build a research center in the country. The first project to be conducted by the university’s research center will examine combining psychedelics and end-of-life distress. Abbey notes that a number of studies have demonstrated that the substances may help individuals suffering from end-of-life distress.
The research center also plans to study whether therapists need to use the drug compounds themselves and experience them in order to be better equipped to facilitate the treatment. Vancouver Island University’s part-time program is set to start this fall, with registration open until March 31, 2022.
Now that major academic institutions such as VIU are beginning to offer courses in psychedelic-assisted therapy, it may just be a matter of time before the psychedelic formulations of sector players such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) experience a surge in demand once the public becomes aware of their approval by regulators.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)